


# NICARAGUA

Cutaneous and mucosal  
Leishmaniasis  
2018



## TLCIc triennium (2016-2018)



### AGE GROUP

11.8% < 5 Y/O  
13.8% ≥ 5 < 10 Y/O  
74.3% > 10 Y/O  
0.1% unspecified

**25.6%** children  
under 10 years old



### GENDER

60.7% Male  
39.3% Female  
**48.1%** men over 10  
years old



### CROSS-BORDER

Shares borders with  
**02** countries in **26**  
municipalities

**31.5%** of the cases  
at the borders



### SURVEILLANCE AND CONTROL

**70.1%** of the population  
in transmission areas

**Decrease** of the CL % in  
children under 10 Y/O  
compared to the previous  
year (Targets of the 2017-  
2022 Plan of Action)



### LEISHMANIA SPECIES

*L. panamensis*  
*L. infantum*



### LUTZOMYIA VECTORS

*L. cruciata*, *L. diabolica*,  
*L. evansi*, *L. gomezi*, *L.*  
*longipalpis*, *L.*  
*nuneztovari anglesi*, *L.*  
*ovallesi*, *L. panamensis*,  
*L. sanguinaria*, *L.*  
*shannoni*, *L. trapidoi*, *L.*  
*ylephiletor*



### PATIENT ASSISTANCE

Laboratory confirmation:  
**94.8%**

Cure rate: **92%**

% of cured patients among  
the treated: **N/I**



### AVAILABLE MEDICINE

Meglumine  
Antimoniate

Amphotericin B  
Liposomal

#### Source:

SisLeish - PAHO/WHO - Data provided by the Ministries of Health -

National Leishmaniasis Programs

Accessed on: 01 November 2019.

N/I: No information available; Y/O: years old